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Abstract
Anesthetic isoflurane has been shown to promote Alzheimer’s disease (AD) neuropathogenesis by inducing caspase
activation and accumulation of b-amyloid (Ab). Phosphorylation of tau protein is another important feature of AD
neuropathogenesis. However, the effects of isoflurane on phosphorylated tau levels remain largely to be determined. We
therefore set out to determine whether isoflurane can increase phosphorylated tau levels. 5 to 8 month-old wild-type and
AD transgenic mice [B6.Cg-Tg (APPswe, PSEN1dE9)85Dbo/J] were treated with 1.4% isoflurane for two hours. The mice brain
tissues were harvested at six, 12 and 24 hours after the anesthesia. For the in vitro studies, primary neurons from wild-type
and the AD transgenic mice were exposed to 2% isoflurane for six hours, and were harvested at the end of anesthesia. The
harvested brain tissues and neurons were subjected to Western blot analysis by which the levels of phosphorylated tau
protein at Serine 262 (Tau-PS262) were determined. Here we show that the isoflurane anesthesia increased Tau-PS262 levels
in brain tissues and primary neurons from the wild-type and AD transgenic mice. Moreover, the isoflurane anesthesia may
induce a greater increase in Tau-PS262 levels in primary neurons and brain tissues from the AD transgenic mice. Finally,
caspase activation inhibitor Z-VAD and Ab generation inhibitor L-685,458 attenuated the isoflurane-induced increases in
Tau-PS262 levels. In conclusion, clinically relevant isoflurane anesthesia increases phosphorylated tau levels, which may
result from the isoflurane-induced caspase activation and Ab generation. These findings will promote more studies to
determine the effects of anesthetics on tau phosphorylation.
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Introduction
Alzheimer’s disease (AD) is an insidious and progressive
neurodegenerative disorder. Currently, there is no cure for AD.
However, if the onset of AD could be delayed by just one year in
those who develop this mind-destroying ailment, the number of
worldwide AD cases would be reduced by 12 million by 2050 (2nd
Alzheimer’s Association International Conference on Prevention
of Dementia in Washington, D.C., June, 2007). Therefore, it is
important to identify any environmental factors which may
promote AD development and AD neuropathogenesis.
An estimated 200 million patients worldwide undergo anesthe-
sia and surgery each year. It has been reported that the age of AD
onset is inversely related to cumulative exposure to anesthesia and
surgery before age 50 [1], even though anesthesia and surgery may
not increase the incidence of AD [2]. Several recent studies also
reported that general anesthesia could be a risk factor for the
development of AD [3,4]. Finally, Tang et al. showed that
anesthesia and surgery may lead to changes in cerebrospinal fluid
biomakers consistent with AD [5]. However, other studies have
suggested different findings [6,7,8]. Therefore, more population
and basic studies defining the role of anesthesia in AD de-
velopment and AD neuropathogenesis are needed [9].
AD neuropathogenesis includes intraneuronal neurofibrillary
tangles that are composed of insoluble aggregates of hyperpho-
sphorylated tau protein [10,11,12], reviewed in [13]. Tau protein
is a microtubule associated protein abundantly found in neuronal
axons. Hyperphosphorylated tau would dissociate from the
microtubule and relocalize in the somatodendritic compartment,
which would then destabilize the microtubule, causing neuronal
dysfunction, neurodegeneration and ultimately functional deficits
[14]. Recent studies have shown that anesthesia-induced hypo-
thermia [15,16,17] and the commonly used anesthetic propofol
[18] and sevoflurane [19] can induce phosphorylation of tau
protein.
Isoflurane, one of the most commonly used inhalational
anesthetics, has been shown to induce caspase activation and
apoptosis, affect amyloid precursor protien (APP) processing,
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tion and impair learning and memory
[20,21,22,23,24,25,26,27,28,29,30]. However, the effects of iso-
flurane on phosphorylated tau levels remain largely to be
determined. In the present studies, we assessed the effects of
isoflurane on phosphorylated tau levels and determined the extent
to which these effects could result from the isoflurane-induced
caspase activation and Ab generation.
Results
Isoflurane Increased Phosphorylated Tau Levels in Brain
Tissues of Wild-type (WT) and AD Transgenic (Tg) Mice
We assessed the effects of isoflurane on phosphorylated tau
levels in the brain tissues of 5–8 month-old WT and AD Tg mice
[B6.Cg-Tg (APPswe, PSEN1dE9)85Dbo/J]. The WT mice were
treated with 1.4% isoflurane for two hours. The brain tissues of the
mice were harvested at six, 12 and 24 hours after the anesthesia,
and were subjected to Western blot analysis. The immunoblotting
of phosphorylated tau protein at serine 262 (Tau-PS262) showed
that the isoflurane anesthesia did not increase the levels of Tau-
PS262 at six hours after the anesthesia (Figure 1a). There was no
significant difference in b-Actin levels between the control
condition and isoflurane-treated mice. Quantification of the
Western blot, based on the ratio of Tau-PS262 and b-Actin,
showed that the isoflurane treatment did not increase Tau-PS262
levels six hours post-anesthesia (Figure 1b). The isoflurane
anesthesia increased the levels of Tau-PS262 at 12 hours after
the anesthesia (Figure 1c). The quantification of the Western blot,
based on the ratio of Tau-PS262 and b-Actin, showed that the
isoflurane anesthesia led to increases in the levels of Tau-PS262 in
the mice brain tissues at 12 hours after the anesthesia: 100% versus
161%, *P=0.049 (Figure 1d). The isoflurane anesthesia increased
the levels of Tau-PS262 in mice brain tissues at 24 hours after the
anesthesia (Figure 1e and Figure 1f): 100% versus 177%,
*P=0.019. The isoflurane anesthesia did not increase the levels
of total tau in WT mice brain tissues (Figure 1g). Finally, we used
tau knockout mice brain tissues as negative controls in our studies
and found that isoflurane anesthesia led to a more visible band in
the Western blot analysis (at about 55 kDa) as compared to control
condition in WT mice brain tissues, whereas tau knockout mice
brain tissues did not show such band (Figure 1h). These data
indicated that the bands (55 kDa) observed following the
isoflurane anesthesia in current experiments were phosphorylated
tau. Taken together, these results suggest that isoflurane anesthesia
may induce tau phosphorylation in WT mice brain tissues, as
evidenced that the isoflurane anesthesia increased the levels of
phosphorylated tau, but not total tau.
Given the findings that the isoflurane anesthesia may increase
Tau-PS262 levels in brain tissues of WT mice, next, we assessed
whether elevated Ab levels could potentiate the isoflurane-induced
increases in Tau-PS262 levels. Five to 8 month-old AD Tg mice
[B6.Cg-Tg(APPswe, PSEN1dE9) 85Dbo/J mice] were treated
with 1.4% isoflurane for two hours. The brain tissues of these mice
were harvested at six, 12 and 24 hours after the anesthesia, and
were subjected to Western blot analysis. The isoflurane anesthesia
increased Tau-PS262 levels in mice brain tissues at six hours after
the anesthesia: 100% versus 588%, **P=0.00687 (Figure 2a and
2b). Similarly, the isoflurane anesthesia led to increases in the
levels of Tau-PS262 in the AD Tg mice brain tissues at 12 hours:
100% versus 377%, **P=0.0016 (Figure 2c and Figure 2d); and
24 hours after the anesthesia: 100% versus 401%, *P=0.044
(Figure 2e and Figure 2f). Taken together, these results suggest that
isoflurane can increase phosphorylated tau levels in the brain
tissues of both WT and AD Tg mice. Moreover, these findings
suggest that isoflurane may induce a greater increase in
phosphorylated tau levels in AD Tg mice brain than WT mice
brain (Figure 1 versus Figure 2), which is consistent with the
findings that Ab can potentiate tau phosphorylation [31].
Isoflurane Increased Phosphorylated Tau Levels in WT
and AD Tg mice Primary Neurons
Given that isoflurane may induce a greater increase in Tau-
PS262 levels in AD Tg mice brain tissues than in WT mice brain
tissues, next we assessed the effects of isoflurane on Tau-PS262
levels in primary neurons from WT and AD Tg mice and further
asked whether elevated Ab level may potentiate the isoflurane-
induced increase in phosphorylated tau levels.
WT mice primary neurons were treated with 2% isoflurane for
six hours. The neurons were harvested at the end of the
experiments and subjected to Western blot analysis. The
immunoblotting of Tau-PS262 showed that the isoflurane
treatment increased Tau-PS262 levels (Figure 3a). There was no
significant difference in b-Actin levels between the control
condition and isoflurane-treated neurons. Quantification of the
Western blot, based on the ratio of Tau-PS262 and b-Actin,
showed that the isoflurane treatment led to increases in Tau-
PS262 levels: 100% versus 234%, *P=0.0162 (Figure 3b).
Next, we assessed the effects of isoflurane on Tau-PS262 levels
in AD Tg mice primary neurons. Immunoblotting of Tau-PS262
showed that the isoflurane treatment increased the levels of Tau-
PS262 in AD Tg mice primary neurons (Figure 3c). There is no
significant difference in b-Actin levels between the control
condition and isoflurane-treated neurons. Quantification of the
Western blot showed that the isoflurane treatment led to increases
in Tau-PS262 levels: 100% versus 243%, *P=0.014 (Figure 3d).
The side by side comparison between WT mice primary
neurons and AD Tg mice primary neurons showed that there were
higher baseline levels of Tau-PS262 in AD Tg mice primary
neurons than in WT mice primary neurons: lanes 1 to 3 versus
lanes 7 to 9 (Figure 3e), 100% versus 1,207%, **P=0.0014
(Figure 3f). The isoflurane anesthesia also led to a greater increase
in Tau-PS262 levels in AD Tg mice primary neurons than in WT
mice primary neurons: lanes 4 to 6 versus lanes 10 to 12
(Figure 3e), 207% versus 1,677%, **P=0.0038 (Figure 3f). Finally,
we were able to show that there were higher Ab levels in the
primary neurons from AD Tg mice than those in the primary
neurons from WT mice (Table 1): 100 versus 62 pmol/ml,
*P=0.019. Taken together, these findings suggest that isoflurane
may induce a greater increase in phosphorylated tau levels when
there are higher Ab levels, e.g., in AD Tg mice.
Cardobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-
fluoromethylketone (Z-VAD) and L-685,458 Attenuated
the Isoflurane-induced Increase in Tau-PS262 levels in WT
and AD Tg mice Primary Neurons
Our previous studies have shown that isoflurane may increase
Ab generation via the effects of isoflurane on inducing caspase
activation and apoptosis [27]. Z-VAD is a caspase activation
inhibitor and L-685,458 is an Ab generation inhibitor (c-secretase
inhibitor). Both Z-VAD and L-685,458 have been shown to
attenuate the isoflurane-induced caspase-3 activation and Ab
accumulation, respectively [27]. Our current studies suggest that
Ab may potentiate the isoflurane-induced increase in phosphor-
ylated tau levels (Figures 1, 2 and 3). We therefore assessed
whether reductions in caspase activation and Ab generation by Z-
VAD and L-685,458, respectively, could attenuate the isoflurane-
Isoflurane and Tau
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39386Figure 1. Isoflurane increases Tau-PS262 levels in brain tissues of WT mice. Isoflurane anesthesia (lanes 2, 4 and 6) does not increase PS262
levels as compared to the control condition (lanes 1, 3 and 5) in the brain tissues of WT mice at six hours after the isoflurane anesthesia. b.
Quantification of the Western blot shows that isoflurane anesthesia (black bar, P=0.782, N.S.) does not increase PS262 levels as compared to the
control condition (white bar). c. Isoflurane anesthesia (lanes 4 to 6) increases Tau-PS262 levels as compared to the control condition (lanes 1 to 3) in
the brain tissues of WT mice at 12 hours after the isoflurane anesthesia. d. Quantification of the Western blot shows that isoflurane anesthesia (black
bar, *P=0.049) increases Tau-PS262 levels as compared to the control condition (white bar). e. Isoflurane anesthesia (lanes 2, 4 and 6) increases Tau-
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mice primary neurons.
Treatment with isoflurane plus Z-VAD led to reductions in the
levels of Tau-PS262 as compared to the treatment with isoflurane
plus dimethyl sulfoxide (DMSO, the vehicle of Z-VAD in the
experiments) (Figure 4a). The quantification of the Western blot
showed that the treatment with isoflurane plus Z-VAD (black bar,
Figure 4b) led to reductions in the levels of Tau-PS262 as
compared to the treatment with isoflurane plus DMSO (white bar,
Figure 4b): 100% versus 43%, **P=0.0057. The treatment with
isoflurane plus L-685,458 (lanes 4 to 6 in Figure 4c; black bar in
Figure 4d) led to reductions in the levels of Tau-PS262 as
compared to the treatment with isoflurane plus DMSO (the
vehicle of L-685,458 in the experiments) (lanes 1 to 3 in Figure 4c,
white bar in Figure 4d): 100% versus 69%, *P=0.0209.
Moreover, treatment with Z-VAD (Figure 4e and 4f, P=0.16,
N.S.) or L-685,458 (Figure 4g and 4h, P=0.219, N.S.) alone did
not significantly affect Tau-PS262 levels as compared to DMSO in
primary neurons from WT mice. These results suggest that
whereas Z-VAD or L-685,458 alone does not significantly affect
phosphorylated tau levels, Z-VAD and L-685,458 may attenuate
the isoflurane-induced increase in phosphorylated tau levels in
primary neurons from WT mice.
Finally, treatment with isoflurane plus Z-VAD led to reductions
in the levels of Tau-PS262 as compared to the treatment with
isoflurane plus DMSO (Figure 5a). The quantification of the
Western blot showed that the treatment with isoflurane plus Z-
VAD (black bar, Figure 5b) led to reductions in the levels of Tau-
PS262 as compared to the treatment with isoflurane plus DMSO
(white bar, Figure 5b): 100% versus 53%, **P=0.0056. The
treatment with isoflurane plus L-685,458 (lanes 4 to 6 in Figure 5c;
black bar in Figure 5d) led to reductions in the levels of Tau-PS262
as compared to the treatment with isoflurane plus DMSO (lanes 1
to 3 in Figure 5c, white bar in Figure 5d): 100% versus 39%,
*P=0.0254. The treatment with Z-VAD or L-685,458 alone did
not significantly alter the levels of Tau-PS262 as compared to
DMSO (Figure 5e, 5f, 5g and 5h). These results suggest that both
Z-VAD and L-685,458 may attenuate the isoflurane-induced
increase in phosphorylated tau levels in primary neurons from AD
Tg mice. Collectively, these findings suggest that isoflurane may
induce caspase activation, apoptosis and Ab accumulation, which
then lead to increase in phosphorylated tau levels.
Discussion
The commonly used inhalation anesthetic isoflurane has been
shown to promote AD neuropathogenesis by inducing caspase
activation, apoptosis, Ab accumulation, neuroinflammation and
mitochondrial dysfunction
[20,21,22,23,24,25,26,27,28,30,32,33,34]. Tau phosphorylation
is part of AD neuropathogenesis, we therefore assessed the
effects of isoflurane on phosphorylated tau levels.
We first found that clinically relevant isoflurane anesthesia
increased levels of phosphorylated tau protein at Serine 262 (Tau-
PS262) in brain tissues of WT (Figure 1) and AD Tg mice (Figure 2)
at six, 12 and 24 hours after the anesthesia. The isoflurane
anesthesia did not significantly affect levels of total tau (Figure 1g),
Tau-PS199, and Tau-PS422 (data not shown) in brain tissues of
WT mice. The findings that the isoflurane anesthesia increased
levels of Tau-PS262 but not total tau suggest that isoflurane may
induce tau phosphorylation in brain tissues of WT mice. We did
not assess effects of isoflurane anesthesia on total tau levels in the
brain tissues of AD Tg mice or in primary neurons from both WT
and AD Tg mice because the objective of these studies is to
determine the role of caspase activation and Ab generation in the
isoflurane-induced increase in phosphorylated tau levels.
Furthermore, we found that the isoflurane anesthesia led to
greater increases in Tau-PS262 levels in AD Tg mice brain tissues
than in WT mice brain tissues. There are higher Ab levels in the
AD Tg mice [B6.Cg-Tg(APPswe, PSEN1dE9) 85Dbo/J mice]
brain tissues than in WT mice brain tissues [35], therefore these
results suggest that Ab may potentiate the isoflurane-induced
increase in phosphorylated tau levels. We did not measure the
effects of isoflurane on total tau levels in brain tissues of AD Tg
mice because the isoflurane anesthesia did not increase total tau
levels in brain tissues of WT mice and we only wanted to compare
the effects of isoflurane on brain phosphorylated tau (e.g., Tau-
PS262) levels between WT and the AD Tg mice.
Next, we found that a clinically relevant concentration of
isoflurane increased levels of Tau-PS262 in primary neurons from
WT and AD Tg mice primary neurons. Moreover, there were
higher levels of Tau-PS262 in the AD Tg mice primary neurons as
compared to WT mice primary neurons following control
condition or isoflurane treatment (Figure 3). Given that there
are elevated Ab levels in AD Tg mice primary neurons as
compared to WT mice primary neurons (Table 1), these results
suggest that isoflurane can increase phosphorylated tau levels
in vitro in primary neurons and moreover isoflurane may induce
a greater increase in phosphorylated tau levels in the condition of
higher Ab levels.
We assessed the effects of isoflurane on Tau-PS262 levels
because phosphorylation at the sites including S262 has been
shown to prevent tau from binding and stabilizing microtubules
[36,37,38,39]. In addition, we also determined the effects of
isoflurane on the levels of Tau-PS199 and Tau-PS422. Even these
sites may not be within the microtubule binding region, the
phosphorylation of these site in tau have been shown to be
associated with severity of neuronal cytopathology in AD [40].
Finally, we were able to show that both caspase activation
inhibitor Z-VAD and Ab generation inhibitor L-685,458 (c-
secretase inhibitor) attenuated the isoflurane-induced increase in
phosphorylated tau levels in WT (Figure 4) and AD Tg (Figure 5)
mice primary neurons. These results suggest that the isoflurane-
induced increase in phosphorylated tau levels may result from the
isoflurane-induced caspase activation and Ab generation. Our
previous studies have shown that isoflurane-induced caspase-3
activation can cause Ab generation [27]. Collectively, we have
postulated that isoflurane induces caspase-3 activation, which
increases Ab generation, and the generated Ab then leads to
increases in phosphorylated tau levels.
Small and Duff have described the hypothesized ‘‘dual pathway
model’’ and ‘‘serial model’’ of Ab and tau causality [13]. In the
PS262 levels as compared to the control condition (lanes 1, 3 and 5) in the brain tissues of WT mice at 24 hours after the isoflurane anesthesia. f.
Quantification of the Western blot shows that isoflurane anesthesia (black bar, *P=0.019) increases Tau-PS262 levels as compared to the control
condition (white bar). g. Isoflurane anesthesia (lanes 4–6 and lanes 10–12) does not increase levels of total tau as compared to the control condition
(lanes 1–3 and lanes 7–9) in the brain tissues of WT mice at 12 and 24 hours after the isoflurane anesthesia. h. Isoflurane anesthesia (lane 5) leads to
a more visible band in the Western blot analysis (at about 55 kDa) as compared to control condition (lane 4) in WT mice brain tissues, whereas tau
knockout (KO) mice brain tissues (lanes 2 and 3, the negative controls) do not show such band. We have averaged results from three to six
independent experiments. WT, wild-type. N=3–6.
doi:10.1371/journal.pone.0039386.g001
Isoflurane and Tau
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39386Figure 2. Isoflurane increases Tau-PS262 levels in brain tissues of AD Tg mice. a. Isoflurane anesthesia (lanes 2 and 4) increases Tau-PS262
levels as compared to the control condition (lanes 1 and 3) in the brain tissues of AD Tg mice at six hours after the isoflurane anesthesia. b.
Quantification of the Western blot shows that isoflurane anesthesia (black bar, **P=0.0069) increases Tau-PS262 levels as compared to the control
condition (white bar). c. Isoflurane anesthesia (lanes 2 and 4) increases Tau-PS262 levels as compared to the control condition (lanes 1 and 3) in brain
tissues of AD Tg mice at 12 hours after the isoflurane anesthesia. d. Quantification of the Western blot shows that isoflurane anesthesia (black bar,
**P=0.0016) increases Tau-PS262 levels as compared to the control condition (white bar). e. Isoflurane anesthesia (lanes 2, 4 and 6) increases Tau-
PS262 levels as compared to the control condition (lanes 1, 3 and 5) in brain tissues of AD Tg mice at 24 hours after the isoflurane anesthesia. f.
Quantification of the Western blot shows that isoflurane anesthesia (black bar, *P=0.044) increases Tau-PS262 levels as compared to the control
condition (white bar). We have averaged results from three independent experiments. AD, Alzheimer’s disease, Tg, transgenic. N=3.
doi:10.1371/journal.pone.0039386.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39386Figure 3. Isoflurane increases Tau-PS262 levels in WT and AD Tg mice primary neurons. a. Isoflurane treatment (lanes 4 and 5) increases
Tau-PS262 levels as compared to the control condition (lanes 1 to 3) in WT mice primary neurons. b. Quantification of the Western blot shows that
isoflurane treatment (black bar, *P=0.0162) increases Tau-PS262 levels as compared to the control condition (white bar). c. Isoflurane treatment (lane
4) increases Tau-PS262 levels as compared to the control condition (lanes 1 to 3) in AD Tg mice primary neurons. d. Quantification of the Western blot
shows that isoflurane treatment (black bar, *P=0.014) increases Tau-PS262 levels as compared to the control condition (white bar) in AD Tg mice
primary neurons. e. The baseline levels of Tau-PS262 levels in AD Tg mice primary neurons (lanes 7 to 9) are higher than those in WT mice primary
neurons (lanes 1 to 3); and isoflurane treatment (lanes 10 to 12) induces a greater increase in Tau-PS262 levels in AD Tg mice primary neurons than in
WT mice primary neurons (lanes 4 to 6). f. Quantification of the Western blot shows that there is a higher baseline Tau-PS262 levels in AD Tg mice
primary neurons (gray bar) than WT mice primary neurons (white bar): **P=0.0014; and isoflurane induces a greater increase in Tau-PS262 levels in
AD Tg mice primary neurons (net bar) than in WT mice primary neurons (black bar): **P=0.0038. We have averaged results from 6 to 12 independent
experiments. WT, wild-type, AD, Alzheimer’s disease, Tg, transgenic. N=6–12.
doi:10.1371/journal.pone.0039386.g003
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environmental factor) can increase Ab levels, which then induce
tau phosphorylation, leading to synaptic loss and dementia. In the
dual pathway model, it has been hypothesized that an insult can
induce Ab elevation and tau phosphorylation simultaneously,
which then separately lead to synaptic loss and dementia [13]. The
findings from the current studies that isoflurane may increase
phosphorylated tau levels via the effects of isoflurane on increasing
Ab levels support the ‘‘serial model’’. Moreover, the findings from
the current studies are consistent with the results from a recent
study that Ab isolated from the AD patient cortex can directly
induce tau phosphorylation and neuritic degeneration [31]. Future
studies may include assessing whether isoflurane can induce an
Ab- and tau-dependent synaptic loss and impairment of learning
and memory to further illustrate the effects of isoflurane on AD
neuropathogenesis. Finally, future studies should also include
assessing whether the isoflurane-induced tau phosphorylation can
induce caspase activation and Ab accumulation, forming a vicious
cycle of tau phosphorylation and caspase activation/Ab genera-
tion.
Planel et al. have shown that isoflurane does not induce tau
hyperphosphorylation in mice [15,17], which is different from the
findings of the current studies. The reason for these different
findings remains largely to be determined. The isoflurane
anesthesia in the studies by Planel et al. [17] consisted of four
exposures of 1.3% isoflurane in 30% O2 for four hours, whereas
the isoflurane anesthesia in the current studies was 1.4% isoflurane
in 100% O2 for two hours. In addition, tau hyperphosphorylation
was determined in mouse brain tissue at two hours or one week
after the isoflurane anesthesia in the studies by Planel et al, while
phosphorylated tau levels were determined in mouse brain tissue
at six, 12 and 24 hours after the isoflurane anesthesia in the
current studies. Furthermore, the isoflurane anesthesia in the
current studies indeed did not increase phosphorylated tau levels
at six hours after the anesthesia in the brain tissues of WT mice.
Taken together, it is conceivable that different anesthesia and
different mouse brain tissue harvest times may account for the
different findings between the current studies and the studies by
Planel et al. [17]. Further studies to test this hypothesis are
warranted.
It is clinically difficult to prove and disprove the relationship
between anesthesia and AD, and prospective clinical studies may
take many years to conduct and analyze. Moreover, clinical studies
have inevitable limitations owing to the characteristics of the
diversity and potential confounding factors e.g., age, outcome
measure, time of investigation, and kind of anesthesia/surgery. In
contrast, animal studies of anesthesia neurotoxicity have less
diversity and fewer confounding factors because animal popula-
tions are more homogeneous and all undergo standardized
procedures and outcome measures in such studies. Therefore,
while it is important to continue clinical studies, there is also a need
to perform animal studies to investigate the potential neurotoxicity
of anesthesia in AD neuropathogenesis. Moreover, the animal
studies will allow us to establish a mechanistic hypothesis,
vulnerable windows, less provocative anesthetics, and potential
treatments, which may facilitate and guide more focused, uniform,
and targeted clinical research. The current research will likely
promote more studies to determine anesthesia neurotoxicity and
the effects of anesthesia, surgery and other perioperative factors on
AD neuropathogenesis.
The studies have several limitations. First, we only determined
the effects of isoflurane anesthesia on the levels of total tau, Tau-
PS262, Tau-PS199 and Tau-PS422 and found that isoflurane
increased levels of Tau-PS262 but not total tau, Tau-PS199, and
Tau-PS422 (data not shown) in brain tissues of WT mice. The
future studies will include the systematic assessment of isoflurane’s
effects on tau phosphorylation at other sites [e.g., AT8 (Ser202/
Thr205), CP13 (Ser202), and PHF-1 (Ser396/Ser404) [18]] as well
as the pathological and functional relevance of the isoflurane-
induced tau phosphorylation. Second, we only determined the
effects of isoflurane anesthesia on total tau levels in brain tissues of
WT mice, but not in brain tissue of AD Tg mice or primary
neurons. We thus may not conclude that isoflurane induces tau
phosphorylation in AD Tg mice or primary neurons. However,
the studies in AD Tg mice and primary neurons primarily aimed
to determine the role of Ab in the isoflurane-induced increase in
phosphorylated tau levels. Nevertheless, the current studies have
established a system and illustrated that isoflurane may induce tau
phosphorylation in brain, and that the isoflurane-induced increase
in phosphorylated tau levels could result from the isoflurane-
induced caspase activation and Ab generation. These findings will
lead to more systematical studies of anesthetics on tau phosphor-
ylation, including assessment of dose- and time-dependent effects
of anesthetics on levels of both phosphorylated tau and total tau.
Finally, our previous studies have shown that isoflurane, but not
desflurane, can induce caspase activation and Ab generation
[25,33,34,41], and propofol can attenuate the isoflurane-induced
caspase activation [42], thus, the future studies will also include the
comparison of the effects of isoflurane and other anesthetics, e.g.,
sevoflurane, desflurane and propofol, on tau phosphorylation.
Isoflurane may induce learning and memory impairment in-
dependent of the isoflurane-induced Ab accumulation and tau
phosphorylation [30,43]. Thus, future studies will include de-
termining the cause-effect relationship of the anesthetics-induced
tau phosphorylation and neurobehavioral deficits by assessing
whether anti-tau treatment(s) can attenuate the isoflurane-induced
neurobehavioral deficits.
Conclusion
In conclusion, we have established a system to determine the
effects of anesthetic on tau phosphorylation, the feature of AD
neuropathogenesis, and underlying mechanisms in vivo and in
primary neurons. We have found that a clinically relevant
concentration of isoflurane can increase phosphorylated tau levels
in primary neurons and the brain tissues of both WT and AD Tg
mice. Ab may potentiate the isoflurane-induced increase in
phosphorylated tau levels. Finally, the isoflurane-induced increa-
ses in phosphorylated tau levels may result from the isoflurane-
Table 1. Ab42 levels in the primary neurons from WT and AD Tg mice.
Primary neurons from WT mice Primary neurons from AD Tg mice
Extracellular Ab42 (pmol/ml) 6262.8 100617.0 (*P=0.019)
Extracellular Ab42 levels are higher in the primary neurons from AD Tg mice than those in the primary neurons from WT mice. N=6.
Ab, b-amyloid protein; WT, wild-type; AD, Alzheimer’s disease; Tg, transgenic.
doi:10.1371/journal.pone.0039386.t001
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would promote more research to investigate the effects of
anesthesia on tau phosphorylation and other AD neuropathogen-
esis, which may include assessing the effects of different anesthetics
(e.g., isoflurane versus desflurane) on the levels of phosphorylated
tau at different epitopes, total tau, tau-associated kinases and
phosphatases in both WT and AD Tg mice, as well as the
functional relevance (e.g., learning and memory impairment).
Future studies may also include employing different methodology,
e.g., immunohistochemistry, to define anesthetic-induced tau
phosphorylation in different brain regions, e.g., the hippocampus
versus the cortex. Ultimately, all of these efforts should facilitate
the design of safer anesthetics and provision of better anesthesia
care to patients, especially senior patients, who are particularly
susceptible to developing postoperative cognitive dysfunction
and AD.
Methods
Mice Anesthesia
Mice were used to assess the potential in vivo effects of isoflurane
on levels of phosphorylated tau protein. The protocol was
approved by the Massachusetts General Hospital (Boston,
Massachusetts) Standing Committee on the Use of Animals in
Research and Teaching. Wild-type (WT) mice (C57BL/6 mice)
and AD transgenic (Tg) mice [B6.Cg-Tg (APPswe, PSEN1-
dE9)85Dbo/J mice] (Jackson Laboratory, Bar Harbor, ME)
(donating from lab of David Borchelt, McKnight Brain Institute,
University of Florida, Gainesville, FL, U.S.A.) at 5–8 months old
were randomized by weight and gender into either an experi-
mental group that received 1.4% isoflurane (a clinically relevant
concentration) plus 100% oxygen for two hours or a control group
that received 100% oxygen for two hours at an identical flow rate
in identical anesthetizing chambers as previously described
[32,44]. We chose this anesthesia because the anesthesia with
1.4% isoflurane plus 100% oxygen for two hours is clinically
relevant and has been shown to induce caspase activation, increase
levels of b-site amyloid precursor protein-cleaving enzyme (BACE)
and Ab, and induce brain inflammation in mice at 5–8 month-old
[32,44]. The anesthesia with 1.4% isoflurane for two hours in mice
was employed to demonstrate whether clinically relevant isoflur-
ane anesthesia, which can induce neurotoxicity [44] and
neurobehavioral deficits [45] in mice, could also induce tau
phosphorylation. We did not use six hours of isoflurane anesthesia
in mice because anesthesia for a longer time (e.g., six hours) may
increase mortality in mice. We did not measure blood gas and pH
values in the current studies because our previous studies had
shown that the same anesthesia with 1.4% isoflurane for two hours
did not significantly alter the values of blood gas and blood
pressure [44]. The mice breathed spontaneously, and the
concentrations of isoflurane and oxygen were measured continu-
ously (Datex, Tewksbury, MA). Hypothermia can lead to tau
phosphorylation [15], therefore, the temperature of the anesthe-
tizing chamber was controlled to maintain rectal temperature of
mice at 3760.5uC. The anesthesia was terminated by discontinu-
ing isoflurane and placing the animals in a chamber containing
100% oxygen until 20 minutes after the return of their righting
reflex. The mice were then returned to their individual home cage
until they were humanely killed. Mice were killed by decapitation,
and the whole brain tissues were harvested and subjected to
Western blot analysis. The numbers of independent experiments
in the moue studies were three to six.
We chose AD Tg mice [B6.Cg-Tg (APPswe, PSEN1-
dE9)85Dbo/J mice] in the experiment to specifically determine
the role of Ab in the effects of isoflurane on the levels of
phosphorylated tau, because the AD Tg mice have elevated Ab
levels owing to mutant transgenes for APP (APPswe: KM594/
5NL) and presenilin 1 (PS1) (dE9:deletion of exon 9) [35]. We used
5 to 8 month-old mice in the current experiments because our
previous studies showed that the isoflurane anesthesia induced
caspase activation and Ab accumulation in the 5 to 8 month-old
WT mice [44]. Moreover, the AD transgenic mice used in the
experiment usually start to develop elevated Ab levels during this
age range (5–8 month-old) [35]. Finally, both WT and AD Tg
mice were age matched in each group.
Primary Neurons
The protocol was approved by the Massachusetts General
Hospital (Boston, Massachusetts) Standing Committee on the Use
of Animals in Research and Teaching. Primary neurons from both
WT and the AD Tg mice [B6.Cg-Tg (APPswe, PSEN1-
dE9)85Dbo/J mice] (donating from lab of David Borchelt,
McKnight Brain Institute, University of Florida, Gainesville, FL,
U.S.A.) were used to assess the potential in vitro effects of isoflurane
on levels of phosphorylated tau protein. WT and AD Tg mice with
a gestation stage of day 15 were killed with carbon dioxide. We
then performed a cesarean section to harvest the neurons as
previously described [33,46]. Seven to 10 days after the harvest,
the neurons were exposed to isoflurane. The numbers of
independent experiments in the neuron studies varied from six
to 12.
Treatment of Neurons
The WT and AD Tg mice primary neurons were treated with
2% isoflurane for six hours under 21% O2 and 5% CO2. We
chose this isoflurane treatment because it is clinically relevant and
had been shown to induce apoptotic cell death and Ab
accumulation in H4 human neuroglioma cells [26,27,42] and in
mice primary neurons [32,33,47] in our previous studies. The
treatment with 2% isoflurane for six hours was employed
to demonstrate whether there is potential association of isoflur-
Figure 4. Z-VAD and L-685,458 attenuate the isoflurane-induced increase in Tau-PS262 levels in WT mice primary neurons. a.
Treatment with isoflurane plus Z-VAD (lanes 6 to 9) leads to reductions in Tau-PS262 levels as compared to treatment with isoflurane plus DMSO
(lanes 1 to 5) in WT mice primary neurons. b. Quantification of the Western blot shows that treatment with isoflurane plus Z-VAD (black bar,
**P=0.0057) leads to a reduction in Tau-PS262 levels as compared to isoflurane plus DMSO (white bar). c. Treatment with isoflurane plus L-685,458
(lanes 4 to 6) leads to reductions in Tau-PS262 levels as compared to treatment with isoflurane plus DMSO (lanes 1 to 3) in WT mice primary neurons.
d. Quantification of the Western blot shows that treatment with isoflurane plus L-685,458 (black bar, *P=0.0209) leads to reductions in Tau-PS262
levels as compared to isoflurane plus DMSO (white bar). e. Z-VAD (lanes 4 to 6) alone does not significantly affect Tau-PS262 levels as compared to
DMSO (lanes 1 to 3) in WT mice primary neurons. f. Quantification of the Western blot shows that Z-VAD (black bar, P=0.16, N.S.) does not
significantly alter Tau-PS262 levels as compared to DMSO (white bar) in WT mice primary neurons. g. L-685,458 (lanes 4 to 6) alone does not
significantly affect Tau-PS262 levels as compared to DMSO (lanes 1 to 3) in WT mice primary neurons. h. Quantification of the Western blot shows that
L-685,458 (black bar, P=0.219, N.S.) does not significantly alter Tau-PS262 levels as compared to DMSO (white bar) in WT mice primary neurons. We
have averaged the results from 6 to 12 independent experiments. WT, wild-type; Z-VAD, Cardobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-
fluoromethylketone; DMSO, Dimethyl sulfoxide. N=6212.
doi:10.1371/journal.pone.0039386.g004
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phosphorylation in primary neurons. We did not use two hours
of isoflurane treatment because treatment with 2% isoflurane for
three hours in vitro had been shown not to induce caspase
activation [26]. Isoflurane was delivered from an anesthesia
machine to a sealed plastic box in a 37uC incubator containing six-
well plates seeded with 0.25 million neurons (80% confluent rate)
in 1.5 ml culture media per well as described before [33,46]. The
control condition for the isoflurane treatment was 21% O2 plus
5% CO2, which has been shown not to induce cell death or Ab
accumulation [25,26,27]. Z-VAD (100 mM) or L-685,458
(0.5 mM) was given to the neurons one hour prior to the isoflurane
treatment. The vehicle for Z-VAD and L-685,458 was dimethyl
sulfoxide (DMSO), thus DMSO served as control condition of Z-
VAD and L-685,458.
Neuron or Tissue Preparation
The neurons and mouse brain tissues were prepared for
Western blot analysis as previously descried [33,44,46]. Specifi-
cally, primary neurons and mouse brain tissues were homogenized
in an immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40) plus protease
inhibitors [(1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml
pepstatin A) (Roche, Indianapolis, IN)]. The lysates were collected,
centrifuged at 13,000 rpm for 15 minutes, and quantified for total
proteins with a bicinchoninic acid protein assay kit (Pierce, Iselin,
NJ).
Western Blot Analysis
The Western blot analysis was used to determine the effects of
isoflurane on the levels of phosphorylated and total tau protein.
The samples were subjected to Western blot analysis as previously
described [33,44,46]. Briefly, 40 mg (primary neurons) or 60 mg
(mouse brain tissues) of each lysate was separated on SDS-PAGE
gels and transferred to polyvinylidene difluoride blots (Bio-Rad,
Hercules, CA) using a semi-dry electrotransfer system (Amersham
Biosciences, San Francisco, CA). The blot was incubated over-
night at 4uC with primary antibody, followed by washes and
incubation with an appropriate secondary antibody, and visualized
with a chemoluminescence system. The levels of phosphorylated
tau protein at Serine 262 (Tau-PS262) were recognized by
antibody Tau (pS262) (55 kDa, 1:1,000, Invitrogen, Carlsbad,
CA). The total tau was recognized by anti-total tau antibody
(55 kDa, 1:1,000, BD Biosciences, Billerica, MA). Antibodies TAU
[pS199] (1:1,000, Invitrogen, Carlsbad, CA) and TAU [pS422]
(1:1,000, Invitrogen) were used to detect levels of Tau-PS199 and
Tau-PS422, respectively. Finally, the antibody to non-targeted
protein b-Actin (42 kDa, 1:5,000, Sigma, St. Louis, MO) was used
to control for loading differences in total protein amounts. The
signal of the Western blot band was detected using the Molecular
Imager VersaDoc MP 5000 System (Bio-Rad Life Science
Research, Hercules, CA). The intensity of signals was analyzed
by using a Bio-Rad image program (Quantity One, Bio-Rad Life
Science Research) or a NIH Image Version 1.37 v (NIH,
Bethesda, MD). Brain tissues from Tau knockout mice were used
as negative controls in the studies to confirm that the bands in the
Western blot following isoflurane treatment represented tau
protein.
Quantification of Ab Using Sandwich ELISA Assay
Levels of secreted Ab42 in the conditioned culture media of
primary neurons were measured with a Sandwich ELISA assay by
using an Ab42 measurement kit (Invitrogen) as described by Dong
et al. [48]. Specifically, 96-well plates were coated with mouse
monoclonal antibodies (mAb) specific to Ab42 (21F12). Following
blocking with Block Ace, wells were incubated overnight at 4uC
with test samples of conditioned cell culture media, and then an
anti-Ab (a-Ab-HR1) conjugated to horseradish peroxidase was
added. Plates were then developed with TMB reagent and well
absorbance was measured at 450 nm. Ab42 levels in test samples
were determined by comparison with the signal from uncondi-
tioned media spiked with known quantities of Ab42.
Statistics
The changes following isoflurane treatment were presented as
percentages of those from the control condition. Data were
expressed as mean6S.D. The number of samples varied from
three to 12, and the samples were normally distributed. We used
a two-tailed t-test to compare the difference between the control
condition and isoflurane treatment, and between DMSO and Z-
VAD or L-685,458. P-values less than 0.05 (*) and 0.01 (**) were
considered statistically significant. The significance testing was
two-tailed, and SAS software (Cary, NC) was used to analyze the
data.
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